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MaThe clinical challenges confronting patients with human immunodeﬁciency virus (HIV) have shifted from acquired immu-
nodeﬁciency syndrome (AIDS)-related illnesses to chronic diseases, such as coronary artery disease, chronic lung disease,
and chronic anemia. With the growing burden of HIV-related heart, lung, and blood (HLB) disease, the National Heart, Lung,
and Blood Institute (NHLBI) recognizes it must stimulate and support HIV-related HLB research. Because HIV offers a
natural, accelerated model of common pathological processes, such as inﬂammation, HIV-related HLB research may yield
important breakthroughs for all patients with HLB disease. This paper summarizes the cardiovascular recommendations of an
NHLBI Working Group, Advancing HIV/AIDS Research in Heart, Lung, and Blood Diseases, charged with identifying scientiﬁc
priorities in HIV-related HLB disease and developing recommendations to promote multidisciplinary collaboration among
HIV and HLB investigators. The working group included multidisciplinary sessions, as well as HLB breakout sessions for
discussion of disease-speciﬁc issues, with common themes about scientiﬁc priorities and strategies to stimulate HLB research
emerging in all 3 groups. (J Am Coll Cardiol 2015;65:738–44) © 2015 by the American College of Cardiology Foundation.T remendous progress in the treatment of hu-man immunodeﬁciency virus (HIV) has ledto increased survival and a dramatic evolu-
tion of the disease (1). The clinical challenges con-
fronting the population have now shifted from
acquired immunodeﬁciency syndrome (AIDS)-related
illnesses to chronic diseases, such as coronary artery
disease, chronic obstructive lung disease, and chronic
anemia (2–7). Many studies have demonstrated that
the risk of developing cardiovascular (CV) dis-
ease in the HIV-positive population is signiﬁcantly
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Factors that potentially contribute to the pathophys-
iology of HIV-related CV disease include the HIV
virus itself, adverse effects of antiretroviral therapy
(ART), and processes such as aging, inﬂammation,
immune activation, microbial translocation, endothe-
lial injury, and disordered coagulation (15–19). These
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AB BR E V I A T I O N S
AND ACRONYM S
AIDS = acquired
immunodeﬁciency syndrome
ART = antiretroviral therapy
CAD = coronary artery disease
CV = cardiovascular
HIV = human
immunodeﬁciency virus
HLB = heart, lung, and blood
NHLBI = National Heart, Lung,
and Blood Institute
NIH = National Institutes
of Health
WG = working group
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739With the growing burden of HIV-related heart,
lung, and blood (HLB) disease, the National Heart,
Lung, and Blood Institute (NHLBI) recognizes that it
must stimulate and support research that addresses
how the chronic phase of HIV affects the HLB sys-
tems. Also, because HIV offers a natural, accelerated
model of common pathological processes, such as
inﬂammation, HIV-related HLB research has the po-
tential to yield important breakthroughs for all pa-
tients with HLB disease. Recently, the NHLBI
assessed its AIDS scientiﬁc portfolio and deter-
mined that it needed to stimulate more
peer-reviewed research in HIV-related HLB disease.
The ﬁrst step to encourage more peer-reviewed
research was to identify the scientiﬁc priorities in
the ﬁeld to guide investigators. Although a small
group of investigators has been pioneering this ﬁeld
for years, the NHLBI also recognized the need to
develop a larger multidisciplinary scientiﬁc commu-
nity to carry out research in the future. This paper
and the Online Appendix summarize the CV recom-
mendations of an NHLBI Working Group (WG), enti-
tled Advancing HIV/AIDS Research in Heart, Lung,
and Blood Diseases, which was charged with both
identifying scientiﬁc priorities in HIV-related HLB
disease and developing recommendations to promote
multidisciplinary collaboration among HIV and HLB
investigators (27).
OVERVIEW OF THE NHLBI WG. The WG included
basic and clinical researchers with scientiﬁc expertise
in HIV and HLB disease, as well as representatives
from the NHLBI, the National Institutes of Health
(NIH) Ofﬁce of AIDS Research, the Center for Scien-
tiﬁc Review, and other NIH institutes and centers. WG
participants were asked to identify the top scientiﬁc
priorities in HIV-related HLB disease, recommend
research approaches to address identiﬁed critical
research gaps, and develop strategies to promote
collaboration and partnerships among the HIV and
HLB scientiﬁc communities.
The group addressed speciﬁc HIV-related HLB
diseases, as well as on cross-cutting multiorgan and
multidisciplinary themes. The CV group focused on
HIV-related coronary artery disease (CAD), the pul-
monary group centered on HIV-related chronic
obstructive pulmonary disease and pulmonary hy-
pertension, and the hematology group addressed
HIV-related anemia and the role of hematopoietic
stem and progenitor cells, both as potential reservoirs
and potential cures for the disease. Common themes
that emerged from the conference included the role
of inﬂammation, direct effects of organisms and
medications, and barriers to multidisciplinary and
cross-institutional collaboration.The CV group focused on the speciﬁc
question “Why does CAD occur at such high
rates in patients with HIV?” In the following
sections, we review the scientiﬁc priorities in
HIV-related CV disease identiﬁed by the WG
and the strategies that they proposed to
advance research in the ﬁeld.
METHODS
During the 2-day meeting, participants were
charged with reﬁning the primary question,
identifying the related scientiﬁc gaps, and
developing research approaches to address
the gaps. The participants were encouraged
to consider basic, clinical, and population
science research approaches. The preliminary rec-
ommendations were presented to the larger group,
and further reﬁned and consolidated into a ﬁnal set of
CV recommendations.
In addition, the WG was asked to provide recom-
mendations on how to stimulate more HIV-related
CV research to further develop this emerging ﬁeld,
including identifying operational challenges to multi-
disciplinary research, developing strategies to enhance
collaboration and engage new investigators, and high-
lighting ways to leverage existing research resources.
RESULTS
SCIENTIFIC THEMES. The top scientiﬁc priorities
focused on epidemiology, pathogenesis, and preven-
tion and treatment. The scientiﬁc recommendations
are discussed by category in the following text and
listed in the Central Illustration.
Ep idemiology . The WG observed that although
there is growing evidence that the incidence and
prevalence of CAD in HIV patients may be higher than
in noninfected people, the actual rate of CAD in the
HIV-infected population, and how it compares with
the noninfected population, is still not well estab-
lished (28–31). Some of the limitations of previous
studies included small numbers of HIV-infected
patients, a deﬁciency of rigorously adjudicated of
CV events, and inconsistent adjustment for con-
founding factors, such as smoking, that occur at much
higher rates in the HIV population. The WG also noted
that there was not enough information to fully
understand the contributions to HIV-related CAD of
traditional risk factors, such as hyperlipidemia,
hypertension, and smoking versus the detrimental
effects of the HIV virus itself, associated inﬂamma-
tion, ART, and coinfections (32,33).
The WG identiﬁed the following major knowledge
gaps in the epidemiology of HIV-related CAD: 1) the
CENTRAL ILLUSTRATION Identiﬁed Scientiﬁc Gaps in HIV-Related CAD and Recommended Research Approaches
EPIDEMIOLOGY PATHOPHYSIOLOGY PREVENTION AND TREATMENT
Scientific Gaps
•  Incidence and prevalence of coronary artery 
disease (CAD) in patients with HIV
•  Interplay of HIV, inflammation, antiretroviral 
therapy (ART), coinfections, and traditional 
risk factors on development of CAD
•  Impact of sex and race on clinical outcomes
Recommended Approaches to Gaps
•  Consolidate current knowledge through 
reviews and meta-analyses
•  Utilize current HIV and cardiovascular (CV) 
studies to examine questions about 
HIV-related CAD
•  Add and adjudicate CV events (CAD, venous 
thrombosis, pulmonary embolism) in HIV 
cohort studies to detect general trends by 
leveraging cohorts with large numbers of HIV 
patients
•  Enrich CV cohort studies with HIV patients to 
allow for detailed assessment of CAD rates 
and the relative contributions of traditional 
and HIV-specific risk factors on the 
development of CAD
•  Examine long-term outcomes and 
determinants of outcomes following CV 
events
•  Conduct studies evaluating HIV-related CV 
disease in women and minorities, and address 
health disparities
Scientific Gaps
•  Mechanisms of the interplay of HIV, 
inflammation, ART, coinfections, and 
traditional risk factors in development and 
progression of CAD
•  Molecular pathways underlying chronic 
inflammation in HIV
•  Impact of microbial translocation, viral 
reactivation, replication, and production on 
lipid metabolism, endothelial function, 
immune senescence, and thrombosis
•  Synergistic effects of smoking on mechanisms 
underlying HIV-related CAD
•  Mechanisms of HIV-related coagulation and 
platelet abnormalities, and thrombosis
•  Novel targets for therapy in HIV-related CAD
•  Need for better animal and molecular models
•  Characterization of atherosclerotic plaque in 
HIV patients 
Recommended Approaches to Gaps
•  Combine pre-clinical development of 
resources with hypothesis-generating  
research
•  Develop more robust animal models to 
explore the relationship between HIV-related 
inflammation and atherosclerosis
•  Pursue mechanistic studies evaluating the 
role of inflammation, microbial translocation, 
and immune activation in HIV-related CAD
Scientific Gaps
•  Potential differences in the prevention and 
treatment of HIV-related CAD
•  Efficacy and effectiveness of evidence-based 
CV therapies in HIV patients
•  Novel therapies to address unique 
pathophysiology of HIV-related CAD
Recommended Approaches to Gaps
•  Add CV outcomes to HIV trials to understand 
the effects of HIV interventions on CAD
•  Increase enrollment of HIV patients into CV 
trials 
•  Collaborate with HIV trial networks early 
during protocol development to address CV 
questions
•  Conduct pilot trials of interventions 
addressing novel risk factors in HIV-related 
CAD, which could be further tested in larger 
studies that include HIV and non-HIV 
populations
•  Develop best practices to incorporate HIV 
testing into clinical trials
•  Leverage existing CV databases, claims data, 
and electronic health records to evaluate 
patterns of care in the prevention, diagnosis, 
and treatment of HIV-related CAD, 
post-event outcomes, and implementation 
of evidence-based CV therapies in the HIV 
population
Shah, M.R. et al. J Am Coll Cardiol. 2015; 65(7):738-44.
HIV ¼ human immunodeﬁciency virus.
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740actual incidence and prevalence of HIV-related CAD;
2) the contributions of various risk factors to the
development of HIV-related CAD; 3) the long-term
outcomes and determinants of outcomes following
HIV-related CV events; and 4) the unique features of
HIV-related CV disease in women and minorities, who
are disproportionately affected by HIV. The WG sug-
gested addressing the identiﬁed gaps by: 1) pursuing
meta-analyses of current studies to fully utilize
available data to estimate the incidence and preva-
lence of HIV-related CV disease; 2) leveraging existing
HIV and CV studies to examine the epidemiology of
HIV-related CAD; 3) including CV endpoints in exist-
ing HIV cohort studies and adjudicating these
events—potential cohort studies included CNICS
(Centers for AIDS Research Network of Integrated
Clinical Systems), MACS (Multi-Center AIDS Cohort
Study), the WIHS (Women’s Interagency HIV Study),and VACS (Veterans Aging Cohort Study); and
4) actively recruiting HIV-positive patients in future
CV cohort studies and identifying patients with HIV
who may already have been recruited in current
cohorts.
Pathophys io logy . The WG noted that HIV might
alter and potentially accelerate the natural history
of the fundamental processes underlying athero-
sclerosis, endothelial dysfunction, and thrombosis
(34–45). The participants also observed that the
mechanisms by which HIV and ART may modify these
processes have still not been fully elucidated. In their
discussions, the WG identiﬁed the following critical
basic science research gaps: 1) the mechanisms by
which HIV, inﬂammation, ART, coinfections, and
traditional risk factors interact in HIV-related CAD;
2) the molecular pathways underlying persistent
chronic inﬂammation in treated HIV, and the
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741role of microbial translocation and viral reactiva-
tion, replication, and production in altering lipid
function and metabolism, endothelial function,
immune senescence, and thrombosis; 3) under-
standing whether the unique pathophysiology of HIV-
related CAD offered distinct therapeutic targets;
4) the synergistic effects of smoking on the patho-
physiological mechanisms contributing to HIV-
related CAD, including abnormalities in coagulation
and thrombosis; and 5) the characterization of the
atherosclerotic plaque in HIV-related CAD through
angiography and imaging.
The WG suggested the following approaches to
address the identiﬁed basic science gaps: 1) develop
more robust animal models to better elucidate
mechanisms of HIV-related CAD; 2) conduct basic
science investigations to understand how inﬂamma-
tion, immune dysfunction, dyslipidemia and other
comorbidities, and gut microbial translocation
contribute to HIV-related CAD; 3) pursue basic
research evaluating how ART may lead to direct and
indirect toxic effects on the vascular endothelium;
and 4) conduct imaging studies to better understand
the pathogenesis of HIV-related CAD.
PREVENTION AND TREATMENT. The WG noted that
there was an urgent need for evidence from ran-
domized clinical trials to effectively prevent and treat
HIV-related CAD (46–50). The WG recommended
pursuing both pilot studies with CV surrogate end-
points to provide preliminary data on novel agents,
and large-scale randomized trials with clinical
outcome endpoints to evaluate evidence-based CAD
therapy in the HIV population. The WG identiﬁed the
following critical scientiﬁc priorities in the preven-
tion and treatment of HIV-related CAD: 1) demon-
strate the safety, efﬁcacy, and effectiveness of
evidence-based therapies for HIV-related CAD;
2) test novel clinical interventions to prevent and
treat HIV-related CAD in the HIV population; and
3) conduct pilot studies in the HIV population
addressing inﬂammation and other novel CV risk
factors that could be further tested in a larger phase
trial that would include both HIV and non-HIV pop-
ulations. The WG recommended addressing the
research gaps in the prevention and treatment of HIV-
related CAD by: 1) including CV outcomes in trials
testing interventions for HIV to understand the ef-
fects of HIV therapies on the development of CAD; 2)
collaborating with HIV-related clinical trial networks
and investigators early during protocol development
to ensure that trials are adequately powered to detect
a meaningful difference in CV outcomes; 3) increasing
the enrollment of HIV patients into CV intervention
trials, to better assess the safety of interventionswhen performing subgroup analyses; 4) incorporating
HIV testing into screening and randomization pro-
cedures to ensure that patients with HIV are identi-
ﬁed; and 5) leveraging existing CV and HIV databases
to pursue outcomes research evaluating patterns of
care in the prevention, diagnosis, and treatment of
HIV-related CAD, post-event outcomes, and imple-
mentation of evidence-based care.
RESEARCH STRATEGY THEMES. The WG strongly
endorsed enhanced communication, collaboration,
and teamwork among investigators from the HIV and
HLB scientiﬁc communities, as well as among the NIH
institutes and centers, to effectively address HIV-
related HLB disease. Speciﬁc recommendations were
as follows:
Communicat ion ; co l laborat ion and teamwork ;
leverag ing resources ; and tra in ing . TheWGurged
engaging both CV and HIV professional societies to
raise awareness in their scientiﬁc communities about
this emerging ﬁeld. The WG recommended expanding
the involvement of CV investigators in current HIV
research networks to broaden network expertise and
promote multidisciplinary communication. The WG
participants also suggested developing a centralized
resource for the scientiﬁc community to access infor-
mation about the NHLBI AIDS program and opportu-
nities for research and funding. In addition, the WG
advised the NHLBI to promote scientiﬁc partnerships
by ensuring that any potential funding opportunities
included multidisciplinary collaboration as part of the
review criteria.
Another major research strategy theme was to
leverage available NIH programs, including existing
cohort studies, clinical trials, and biorepositories. The
WG recommended enriching HIV cohorts with adju-
dicated CV endpoints and increasing the enrollment
of HIV patients into CV studies.
The WG recognized that in order for the ﬁeld to
advance, there needed to be concerted efforts to
develop a scientiﬁc community with expertise in both
HIV and CV disease. The WG encouraged investing
resources in training early stage investigators
and developing funding opportunities that would
encourage multidisciplinary mentorship and collab-
oration among the HIV and CV scientiﬁc commu-
nities. The WG suggested that early-stage HIV and CV
investigators receive cross-disciplinary training to
learn fundamental skills in both ﬁelds.
NHLBI AIDS PROGRAM: EVALUATING PERFORMANCE.
After receiving the WG recommendations, the NHLBI
staff recognized the importance of developing a sys-
tem to evaluate whether the AIDS program effec-
tively stimulates high quality peer-reviewed research
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tively develop performance measures to gauge how
well the AIDS portfolio was being stimulated. The
performance measures included the number of new
HIV-related HLB peer-reviewed applications and
awards, and whether applications and awards
addressed the identiﬁed scientiﬁc gaps. Other per-
formance measures included the number of new
investigators entering the ﬁeld and whether the
supported research led to publications, citations, or
changes in clinical practice guidelines. The NHLBI
AIDS team also determined that regular portfolio
analyses and assessment of performance measures
were essential to promote a continuous cycle of
learning and improvement of the AIDS program.
Regular systematic reviews would allow the NHLBI to
reﬁne approaches on how best to stimulate peer-
reviewed HIV-related HLB research, identify future
scientiﬁc priorities, and make evidence-based de-
cisions about future research investments.
CONCLUSIONS AND DISCUSSION
The increased survival of patients with HIV has
reshaped the urgent public health needs of this pop-
ulation and triggered new research questions and
scientiﬁc priorities. The NHLBI has a unique oppor-
tunity and an important mandate to take a leadership
role in responding to the evolving research demands
of HIV-related HLB disease. The WG recommenda-
tions laid the foundation for the next phase of the
NHLBI AIDS program by identifying the key scientiﬁc
priorities and strategic gaps that needed to be
addressed in order to effectively stimulate HIV-
related HLB research. In response to the WG recom-
mendations, the NHLBI has developed an NHLBI AIDS
website, made public presentations at professional
meetings, such as the American Heart Association andthe Conference on Retroviruses and Opportunistic
Infections, released broad-based, multidisciplinary
basic science and clinical research funding opportu-
nities in HIV-related HLB disease, funded studies in
HIV patients that evaluate CV interventions being
tested in non-HIV populations, and launched the
largest HIV-related CV randomized clinical trial to
date (53–60). These collaborative efforts and actions
have resulted in growth in the NHLBI AIDS scientiﬁc
portfolio—including an increase in the number of
peer-reviewed HIV-related HLB applications and
awards, and a rise in the number of investigators
entering the ﬁeld. Importantly, the NHLBI is funding
multidisciplinary partnerships between HIV and HLB
investigators and is partnering with other NIH in-
stitutes to support large HIV-related HLB scientiﬁc
programs and clinical trials. Finally, the NHLBI is
regularly reviewing and assessing its HIV-related HLB
scientiﬁc portfolio to assess progress, cultivate new
areas for research, and plan for the future.
The WG was a pivotal event in the launch of the
next chapter of the NHLBI AIDS program. Guided by
the WG recommendations, the NHLBI will continue
its efforts to stimulate innovative research, develop
multidisciplinary scientiﬁc partnerships, and sup-
port cutting edge discoveries in HIV-related HLB
disease. In making these valuable research in-
vestments, the NHLBI looks forward to invaluable
returns—improved survival and quality of life, not
only for patients with HIV, but for all patients with
HLB disease.
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